Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib.
暂无分享,去创建一个
J. Blay | J. Nemunaitis | M. Heinrich | S. George | J. Zalcberg | M. Mehren | H. Gelderblom | P. Schöffski | S. Bauer | R. Ruiz-Soto | Khalil Choucair | H. Achour
[1] M. Heinrich,et al. INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥ 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753) , 2019, Annals of Oncology.
[2] Stacie L. Bulfer,et al. Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. , 2019, Cancer cell.
[3] M. van de Rijn,et al. Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs) , 2019, Clinical Sarcoma Research.
[4] B. Vincenzi,et al. Secondary KIT mutations: the GIST of drug resistance and sensitivity , 2019, British Journal of Cancer.
[5] J. Fletcher,et al. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours , 2019, British Journal of Cancer.
[6] M. Heinrich,et al. Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases. , 2018, Pharmacology & therapeutics.
[7] O. Rosen,et al. Initial results of phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] O. Rosen,et al. Abstract CT029: Pharmacokinetic (PK), safety, and tolerability profile of DCC-2618 in a phase I trial supports 150mg QD selected for a pivotal phase III trial in gastrointestinal stromal tumor (GIST) , 2018, Clinical Trials.
[9] C. Paweletz,et al. Phase Ib study of rapid alternation of sunitinib (SU) and regorafenib (RE) in patients (pts) with advanced gastrointestinal stromal tumor (GIST). , 2018 .
[10] G. Stefanzl,et al. The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis , 2018, Haematologica.
[11] A. Le Cesne,et al. Recent advances in managing gastrointestinal stromal tumor , 2017, F1000Research.
[12] A. Astolfi,et al. The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST) , 2017, Journal of Translational Medicine.
[13] C. Tzen,et al. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17 , 2017, Oncotarget.
[14] S. Sleijfer,et al. Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Tr , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] G. Stefanzl,et al. The Multi-Kinase Inhibitor DCC-2618 Inhibits Proliferation and Survival of Neoplastic Mast Cells and Other Cell Types Involved in Systemic Mastocytosis , 2016 .
[16] J. Fletcher. KIT Oncogenic Mutations: Biologic Insights, Therapeutic Advances, and Future Directions. , 2016, Cancer research.
[17] E. Wardelmann,et al. Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] P. Meltzer,et al. Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. , 2016, JAMA oncology.
[19] K. Søreide,et al. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. , 2016, Cancer epidemiology.
[20] M. Heinrich,et al. SDHC methylation in gastrointestinal stromal tumors (GIST): a case report , 2015, BMC Medical Genetics.
[21] J. Sicklick,et al. Epidemiology of Gastrointestinal Stromal Tumors in the Era of Histology Codes: Results of a Population-Based Study , 2014, Cancer Epidemiology, Biomarkers & Prevention.
[22] J. Fletcher,et al. Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients , 2014, Clinical Cancer Research.
[23] C. Antonescu,et al. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Blay,et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.
[25] Xiaohong Liu,et al. The expression of KIT receptor dimers in gastrointestinal stromal tumors independent of c-kit mutation and SCF expression is associated with high-risk stratification. , 2012, Oncology letters.
[26] J. Blay,et al. Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era , 2012, Clinical Cancer Research.
[27] Aki Vehtari,et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. , 2012, JAMA.
[28] D. Ksienski. Imatinib Mesylate: Past Successes and Future Challenges in the Treatment of Gastrointestinal Stromal Tumors , 2011, Clinical Medicine Insights. Oncology.
[29] J. Lasota,et al. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. , 2009, Archives of pathology & laboratory medicine.
[30] Yan Zhang,et al. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients , 2009, Proceedings of the National Academy of Sciences.
[31] C. Antonescu,et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] J. Fletcher,et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST , 2008, The Journal of pathology.
[33] C. Antonescu. Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas , 2008, Modern Pathology.
[34] J. Crowley,et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] A. Hartmann,et al. Epithelioid gastric stromal tumours of the antrum in young females with the Carney triad: a report of three new cases with mutational analysis and comparative genomic hybridization. , 2007, Oncology reports.
[36] J. Fletcher,et al. KIT mutations in GIST. , 2007, Current opinion in genetics & development.
[37] Xin Huang,et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.
[38] J. Fletcher,et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] G. Antoch,et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib , 2005, International journal of cancer.
[40] H. Joensuu,et al. NF1-Associated Gastrointestinal Stromal Tumors Have Unique Clinical, Phenotypic, and Genotypic Characteristics , 2005, The American journal of surgical pathology.
[41] M. Heinrich,et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] G. Kanel,et al. Gastrointestinal stromal tumors: Clinical profile, pathogenesis, treatment strategies and prognosis , 2005, Journal of gastroenterology and hepatology.
[43] C. Antonescu,et al. Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation , 2005, Clinical Cancer Research.
[44] C. Leutner,et al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. , 2005, The Lancet. Oncology.
[45] P. Marynen,et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. , 2005, Gastroenterology.
[46] Rossella Bertulli,et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial , 2004, The Lancet.
[47] J. Fletcher,et al. Biology of gastrointestinal stromal tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] A. D. Van den Abbeele,et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] Samuel Singer,et al. PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.
[50] R. Pazdur,et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[51] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[52] J. Buckner,et al. Contrast of Response to Dacarbazine, Mitomycin, Doxorubicin, and Cisplatin (DMAP) Plus GM-CSF Between Patients with Advanced Malignant Gastrointestinal Stromal Tumors and Patients with Other Advanced Leiomyosarcomas , 2002, Cancer investigation.
[53] S. Hirota,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.
[54] Robin L. Jones,et al. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. , 2017, Future oncology.
[55] B. V. Van Tine,et al. Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review. , 2017, Journal of gastrointestinal oncology.
[56] R. Roskoski. Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. , 2016, Pharmacological research.
[57] G. Demetri,et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. , 2002, Human pathology.